Papers - SATO Atsushi
-
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
Yukinori Ozaki, Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano
Int J Clin Oncol 2024.3
-
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022
Keita Uchino, Shingo Tamura, Shoji Kimura, Keisuke Shigeta, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Yuji Miura
Int J Clin Oncol 2024.3
-
Efectiveness and safety of primary prophylaxis with G‑CSF after induction therapy for acute myeloid leukemia: a systematic review and meta‑analysis of the clinical practice guidelines for the use of G‑CSF 2022 from the Japan society of clinical oncology
Tomoya Maeda、Yuho Najima、Yutaro Kamiyama、Shinji Nakao、Yukinori Ozaki、Hiroshi Nishio、Kenji Tsuchihashi、Eiki Ichihara、Yuji Miumra、Makoto Endo、Dai Maruyama、Tatsuhiro Yoshinami1、Nobuyuki Susumu、Munetaka Takekuma、Takashi Motohashi、Mamoru Ito、Eishi Baba、Nobuaki Ochi、Toshio Kubo、Keita Uchino、Takahiro Kimura、Shinobu Tamura、Hitomi Nishimoto、Yasuhisa Kato、Atsushi Sato、Toshimi Takano、Shingo Yano
Int J Clin Oncol 2024.3
-
Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201)
Hiroo Imai, Yasuhiro Sakamoto, Shin Takahashi, Hiroyuki Shibata, Atsushi Sato, Kazunori Otsuka, Kenji Amagai, Masanobu Takahashi, Takuhiro Yamaguchi, Chikashi Ishioka
BMC Cancer 24 ( 1 ) 2024.2
-
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022
Eiki Ichihara, Nobuaki Ochi, Go Makimoto, Kenichiro Kudo, Daijiro Harada, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu , Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura , Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Toshio Kubo
Int J Clin Oncol 2024.2
-
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study
Ryohei Kawabata, Keisho Chin, Daisuke Takahari, Hisashi Hosaka, Osamu Muto, Yoshiaki Shindo, Naoki Nagata, Hiroshi Yabusaki, Hiroshi Imamura, Shunji Endo, Tomomi Kashiwada, Masato Nakamura, Jun Hihara, Michiya Kobayashi, Tamotsu Sagawa, Soh Saito, Atsushi Sato, Takeshi Yamada, Naohiro Okano, Ken Shimada, Masashi Matsushima, Masato Kataoka, Shigemi Matsumoto, Masahiro Goto, Masahito Kotaka, Takeshi Shiraishi, Hiromichi Yamai, Fumio Nagashima, Naoki Ishizuka, Kensei Yamaguchi
Gastric Cancer 26 ( 6 ) 1020 - 1029 2023.8
-
Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy
Junichi Nakagawa， Takenori Takahata， Yu Chen， Kensuke Saito， Kosuke Kamata， Takuto Tachita，Satoru Yamashita， Keigo Saito， Kayo Ueno， Atsushi Sato， Hirotake Sakuraba， Takenori Niioka
Cancer Chemother Pharmacol 92 ( 5 ) 391 - 398 2023.8
-
アントラサイクリン系抗がん剤の血管外漏出にデクスラゾキサンを使用した4例の報告
高畑武功，佐藤 温，照井一史，中原潤一，兵頭 塁，粟津朱美，阿保恵美子，蓮井研吾，陳 豫，斎藤絢介，佐々木洸太
癌と化学療法 50 ( 4 ) 467 - 471 2023.4
-
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada, Michio Nakamura, Osamu Muto, Susumu Sogabe, Yoshiaki Shindo, Atsushi Ishiguro, Atsushi Sato, Yasushi Tsuji, Masayoshi Dazai, Hiroyuki Okuda, Takashi Meguro, Kazuaki Harada, Mari Sekiguchi, Kazufumi Okada, Yoichi M Ito, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Oncologist 27 ( 8 ) e642 - e649 2022.8
-
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer
Shintaro Nakano, Yasuyuki Kawamoto, Satoshi Yuki, Kazuaki Harada, Takuto Miyagishima, Susumu Sogabe, Masayoshi Dazai, Atsushi Sato, Atsushi Ishiguro, Michio Nakamura, Shinya Kajiura, Yasuo Takahashi, Miki Tateyama, Kazuteru Hatanaka, Yasushi Tsuji, Takahide Sasaki, Yoshiaki Shindo, Tomoe Kobayashi, Isao Yokota, Naoya Sakamoto, Yuh Sakata, Yoshito Komatsu
BMJ Open 12 ( 5 ) e048833 - e048833 2022.5
-
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
Yasuyuki Kawamoto, Satoshi Yuki, Takashi Meguro, Kazuteru Hatanaka, Minoru Uebayashi, Michio Nakamura, Hiroyuki Okuda, Ichiro Iwanaga, Takashi Kato, Shintaro Nakano, Atsushi Sato, Kazuaki Harada, Koji Oba, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
27 ( 5 ) 340-e374 - 340-e374 2022.5
-
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer
Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Yasuyuki Kawamoto, Kazuaki Harada, Shintaro Nakano, Rika Saito, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Support Care Cancer 2022.3
-
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
Denda T, Takashima A, Gamoh M, Iwanaga I, Komatsu Y, Takahashi M, Nakamura M, Ohori H, Sakashita A, Tsuda M, Kobayashi Y, Baba H, Kotake M, Ishioka C, Yamada Y, Sato A, Yuki S, Morita S, Takahashi S, Yamaguchi T, Shimada K
154 296 - 306 2021.9
-
Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report
Sasaki K, Yokota Y, Isojima T, Fujii M, Hasui K, Y Chen, Saito K, Takahata T, Kindaichi S, Sato A
Asian Pacific Society of Respirology 9 ( 7 ) 2021.9
-
Multicenter Analysis of Hand Foot Syndrome by CapeOx Therapy Using Telephone Support Program after Radical Colon Cancer Surgery
Junichi Koike, Kaoru Furushima, Shin Sasaki, Atsushi Satoh, Kazuteru Watanabe, Mitsunori Ushigome, Tomoaki Kaneko, Hiroyuki Shiokawa, Satoru Kagami, Mari Oba and Kimihiko Funahashi
74 ( 5 ) 287 - 295 2021.5
-
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C
Cancer science 112 ( 4 ) 1567 - 1578 2021.4
-
Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy.
Nakagawa J, Takahata T, Hyodo R, Chen Y, Hasui K, Sasaki K, Saito K, Ueno K, Hosoi K, Terui K, Sato A, Niioka T
Scientific reports 11 ( 1 ) 785 2021.1
-
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
M Ueno, T Ioka, A Sato, et al.
Cancer Medicine 24 ( 9 ) 9396 - 9408 2020.10
-
A Case of Non-Resectable Pancreatic Cancer With Multiple Hepatic Metastases Treated With FOLFIRINOX Therapy and Conversion Surgery
Gan To Kagaku Ryoho 46 ( 13 ) 2551 - 2553 2019.12
-
[A Case of Non-Resectable Pancreatic Cancer with Multiple Hepatic Metastases Treated with FOLFIRINOX Therapy and Conversion Surgery].
Akaishi T, Ishido K, Kimura N, Nagase H, Odagiri T, Fujita H, Chen Y, Saito K, Takahata T, Sato A, Hakamada K
Gan to kagaku ryoho. Cancer & chemotherapy 46 ( 13 ) 2551 - 2553 2019.12
-
Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Atsuo Takashima, Kohei Shitara, Kazumasa Fujitani, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hirofumi Fujii, Kei Muro, Taito Esaki, Yasuhiro Choda, Toshimi Takano, Keisho Chin, Atsushi Sato, Masahiro Goto, Norimasa Fukushima, Takuo Hara, Nozomu Machida, Manabu Ohta, Narikazu Boku, Masashi Shimura, Satoshi Morita, Wasaburo Koizumi
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 22 ( 1 ) 155 - 163 2019.1
-
癌化学療法施行患者における安全性評価と苦痛度評価の差異に関する患者因子の検討
佐藤温、高畑武功、斎藤絢介 他
癌と化学療法 45 ( 6 ) 955 - 960 2018.6
-
[Analysis of the Patient Factors in the Difference between Adverse Effect Evaluation and Distress Evaluation in Cancer Patients Receiving Chemotherapy].
Tanaka K, Sato A, Takahata T, Kudo F, Saito K, Yu C
Gan to kagaku ryoho. Cancer & chemotherapy 45 ( 6 ) 955 - 960 2018.6
-
GemcitabinおよびS-1治療抵抗性膵癌に対するWeekly Paclitaxel療法の後方視的検討
佐藤温、高畑武功、斎藤絢介、陳豫
癌と化学療法 45 ( 5 ) 817 - 821 2018.5
-
[Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer].
Takahata T, Sato A, Yu C, Saito K
Gan to kagaku ryoho. Cancer & chemotherapy 45 ( 5 ) 817 - 821 2018.5
-
A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factors.
Sasaki T, Kato Y, Sato A, Usui N, Baba E, Takano T, Susumu N, Ohnishi K, Nishimoto H, Kiura K
Journal of pharmaceutical health care and sciences 4 2 2018
-
Health-related quality of life in a randomized phase Ⅲ study of gemcitabine plus S-1,S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer:GEST study.
Yasuhiro Hagiwara,Yasuo Ohashi 他
ESMO Open Cancer Horizons 2017.3
-
Assessment of Injection Site Reactions for Peripheral Intravenous Oxaliplatin Infusion and Potential Remedies.
Handa S, Kuroiwa R, Miyano M, Shimizu H, Kamei D, Takei H, Sonou H, Yamamoto H, Murayama J, Sato A, Kato Y
Gan to kagaku ryoho. Cancer & chemotherapy 43 ( 8 ) 985 - 8 2016.8
-
[Withdrawal of Anticancer Therapy in Advanced Disease Because of Side Effects].
Sato A, Chin Y, Kudo F, Saito K, Takahata T
Gan to kagaku ryoho. Cancer & chemotherapy 43 ( 7 ) 798 - 802 2016.7
-
Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
Koichi Takayama,Shunichi Sugawara,Yasuo Saijo,Makoto Maemondo,Atsushi Sato,Shinzo Takamori,Taishi Harada,Tetsuro Sasada,Tatsuyuki Kakuma,Junji Kishimoto,Akira Yamada,Masanori Noguchi,Kyogo Itoh,and Yoichi Nakanishi
Journal of Immunology Reseach 7 - 7 2016.1
-
A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
Yoshida M, Takagane A, Miyake Y, Shimada K, Nagata N, Sato A, Ogata Y, Fukunaga M, Otsuka K, Takahashi T, Matsumoto H, Kagimura T, Tsuji A
Oncology 91 ( 1 ) 24 - 30 2016
-
Study protocol of the TRICOLORE trial:a randomized phase Ⅲ study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1,irinotecan,and bevacizumab as first-line therapy for metastatic colorectal cancer.
Yoshito Komatsu、Chikashi Ishioka、Ken Shimada、Yasuhide Yamada、Makio Gamoh、Atsushi Sato、Tatsuro Yamaguchi、Satoshi Yuki、Satoshi Morita、Shin Takahashi、Rei Goto and Minoru Kurihara
BMC Cancer 2015 Vol.15 15 626 - 626 2015.9
-
A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
Nakayama N, Sato A, Tanaka S, Shimada K, Konishi K, Sasaki E, Hibi K, Ichikawa H, Kikuchi Y, Sakuyama T, Sekikawa T, Hayashi K, Nishina H, Tokyo Cooperative Oncology Group, Tokyo, Japan.
Investigational new drugs 33 ( 4 ) 954 - 62 2015.8
-
A phase Ⅱ study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer:the TCOG-GI 0802 study.
Nakayama N、Sato A、Tanaka S、Shimada K、Konishi K、Sasaki E、Hibi K、Ichikawa H、Kikuchi Y、Sakuyama T、Sekikawa T、Hayashi K、Nishina H
Invest New Drugs 2015 Aug 33(4) 33 ( 4 ) 954 - 962 2015.5
-
[Second-line chemotherapy for advanced pancreatic cancer].
Sato A, Saito K, Takahata T
Gan to kagaku ryoho. Cancer & chemotherapy 42 ( 4 ) 403 - 7 2015.4
-
[Introduction of oxaliplatin for treating unresectable advanced or recurrent gastric cancer in clinical practice].
Sato A
Gan to kagaku ryoho. Cancer & chemotherapy 42 ( 4 ) 443 - 6 2015.4
-
[Topoisomerase II inhibitors (anthracyclines)].
Sato A, Takahata T, Saito K
Nihon rinsho. Japanese journal of clinical medicine 73 Suppl 2 178 - 83 2015.2
-
[Microtubule polymerization inhibitors].
Takahata T, Sato A, Saito K, Yamagata K
Nihon rinsho. Japanese journal of clinical medicine 73 Suppl 2 162 - 6 2015.2
-
[Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF].
Hanada N, Tanaka S, Takahata T, Sato A
Gan to kagaku ryoho. Cancer & chemotherapy 41 ( 6 ) 702 - 6 2014.6
-
A Prospective Observational Study to Examine the Relationship between Quality of Life and Adverse Events of First-line Chemotherapy Plus Cetuximab in Patients with KRAS Wild-type Unresectable Metastatic Colorectal Cancer: QUACK Trial.
Ooki A, Ando M, Sakamoto J, Sato A, Fujii H, Yamaguchi K.
Japan Journal Clinical 44 ( 4 ) 383 - 387 2014.2
-
肝転移を伴う切除不能胆管癌に対して化学療法が著効した1例
脇屋太一,豊木嘉一,石戸圭之輔,工藤大輔,木村憲央,矢越雄太,石黒敦,高畑武功,佐藤温,袴田健一
癌と化学療法 40 ( 12 ) 1753 - 1755 2013.11
-
[A case of unresectable biliary tract cancer with liver metastasis that exhibited an effective response to chemotherapy].
Wakiya T, Toyoki Y, Ishido K, Kudo D, Kimura N, Yakoshi Y, Ishiguro A, Takahata T, Sato A, Hakamada K
Gan to kagaku ryoho. Cancer & chemotherapy 40 ( 12 ) 1753 - 5 2013.11
-
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao, Tomotaka Shimamura, Masayuki Sho, Masayuki Kitano, Ann-Lii Cheng, Kazuhiro Mizumoto, Jen-Shi Chen, Junji Furuse, Akihiro Funakoshi, Takashi Hatori, Taketo Yamaguchi, Shinichi Egawa, Atsushi Sato, Yasuo Ohashi, Takuji Okusaka, Masao Tanaka
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31 ( 13 ) 1640 - 1648 2013.5
-
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Kensei Yamaguchi, Akira Sawaki, Toshihiko Doi, Taroh Satoh, Yasuhide Yamada, Yasushi Omuro, Tomohiro Nishina, Narikazu Boku, Keisho Chin, Yasuo Hamamoto, Hiroya Takiuchi, Yoshito Komatsu, Shigehira Saji, Wasaburo Koizumi, Yoshinori Miyata, Atsushi Sato, Eishi Baba, Takao Tamura, Takashi Abe, Atsushi Ohtsu
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 16 ( 2 ) 175 - 182 2013.4
-
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Yamaguchi K1, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, Takiuchi H, Komatsu Y, Saji S, Koizumi W, Miyata Y, Sato A, Baba E, Tamura T, Abe T, Ohtsu A.
Gastric Cancer 16 ( 2 ) 175 - 182 2013.4
-
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Yamaguchi K, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, Takiuchi H, Komatsu Y, Saji S, Koizumi W, Miyata Y, Sato A, Baba E, Tamura T, Abe T, Ohtsu A
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 16 ( 2 ) 175 - 82 2013.4
-
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow (DCBM)due to bone metastasis, with DIC recovery by administration of S-1 and docetaxel].
Hiromi Imataka, Atsushi Sato, Kazuyuki Hamada, Norikazu Takeda, Hiroshi Nemoto
Gan to kagaku ryoho. Cancer & chemotherapy 40 ( 2 ) 241 - 243 2013.2
-
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow (DCBM)due to bone metastasis, with DIC recovery by administration of S-1 and docetaxel].
Imataka H, Sato A, Hamada K, Takeda N, Nemoto H
Gan to kagaku ryoho. Cancer & chemotherapy 40 ( 2 ) 241 - 3 2013.2
-
[Medical treatment for gastrointestinal stromal tumor (GIST) in Japan].
Sato A, Hamada K, Imataka H
Gan to kagaku ryoho. Cancer & chemotherapy 39 ( 5 ) 708 - 12 2012.5
-
[Skin toxicity].
Sato A, Hamada K, Imataka H
Gan to kagaku ryoho. Cancer & chemotherapy 38 ( 11 ) 1767 - 72 2011.11
-
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
Atsushi Sato, Toshihiko Doi, Narikazu Boku, Ken Kato, Yoshito Komatsu, Kensei Yamaguchi, Kei Muro, Yasuo Hamamoto, Wasaburo Koizumi, Nobuyuki Mizunuma, Hiroya Takiuchi
Gan to kagaku ryoho. Cancer & chemotherapy 38 ( 4 ) 561 - 569 2011.4
-
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
Sato A, Doi T, Boku N, Kato K, Komatsu Y, Yamaguchi K, Muro K, Hamamoto Y, Koizumi W, Mizunuma N, Takiuchi H
Gan to kagaku ryoho. Cancer & chemotherapy 38 ( 4 ) 561 - 9 2011.4
-
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Toshihiko Doi, Narikazu Boku, Ken Kato, Yoshito Komatsu, Kensei Yamaguchi, Kei Muro, Yasuo Hamamoto, Atsushi Sato, Wasaburo Koizumi, Nobuyuki Mizunuma, Hiroya Takiuchi
Japanese journal of clinical oncology 40 ( 10 ) 913 - 920 2010.10
-
アミオダロン塩酸塩速崩錠「ＴＨ｝の健康成人における薬物動態
高野和彦，長井晶彦，佐藤隆，佐藤温
診療と新薬 47 ( 9 ) 898 - 903 2010.9
-
[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Japanese patients with bone metastases--The Japanese version of the EORTC QLQ-BM22].
Takefumi Satoh, Kunihiko Kobayashi, Taisuke Hori, Shinsuke Iida, Atsushi Sato, Hiroshi Ishiguro, Edward Chow, Kojiro Shimozuma
Gan to kagaku ryoho. Cancer & chemotherapy 37 ( 8 ) 1507 - 1512 2010.8
-
[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Japanese patients with bone metastases--The Japanese version of the EORTC QLQ-BM22].
Satoh T, Kobayashi K, Hori T, Iida S, Sato A, Ishiguro H, Chow E, Shimozuma K
Gan to kagaku ryoho. Cancer & chemotherapy 37 ( 8 ) 1507 - 12 2010.8
-
[Clinical development of oral chemotherapeutic agents for advanced gastric cancer].
Sato A, Nakamachi M, Imataka H, Hamada K
Gan to kagaku ryoho. Cancer & chemotherapy 37 ( 7 ) 1192 - 7 2010.7
-
Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology.
Takuro Shimbo, Tsuguya Fukui, Chikashi Ishioka, Kohji Okamoto, Takahiro Okamoto, Shingo Kameoka, Atsushi Sato, Masakazu Toi, Kunihiko Matsui, Toshihiko Mayumi, Shigetoyo Saji, Masaru Miyazaki, Yuichi Takatsuka, Koichi Hirata
International journal of clinical oncology 15 ( 3 ) 227 - 233 2010.6
-
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Wasaburo Koizumi, Toshikazu Akiya, Atsushi Sato, Toshikazu Sakuyama, Eisaku Sasaki, Takashi Tomidokoro, Tsutomu Hamada, Mototsugu Fujimori, Yoshinori Kikuchi, Ken Shimada, Tetsuya Mine, Kensei Yamaguchi, Tsuneo Sasaki, Minoru Kurihara
Cancer chemotherapy and pharmacology 65 ( 6 ) 1093 - 1099 2010.5
-
アミオダロン塩酸塩速崩錠100mg{TH」及びアミオダロン塩酸塩速崩錠50mg「TH」の生物学的同等性試験
蓮沼智子，豊田幹男，土持一郎，小林亮一，佐藤 隆，佐藤 温
診療と新薬 47 ( 4 ) 369 - 379 2010.4
-
The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer.
Yoko Ishihara, Kenichi Matsunaga, Hiroko Iijima, Go Hasegawa, Toshimitsu Suzuki, Atsushi Sato, Tomowo Kobayashi, Meng Yang, Robert M Hoffman
Anticancer research 30 ( 2 ) 403 - 408 2010.2
-
[First/second/third-line chemotherapy with molecular targeted drugs for colorectal cancer].
Sato A, Nakamachi M, Imataka H
Gan to kagaku ryoho. Cancer & chemotherapy 36 ( 8 ) 1242 - 6 2009.8
-
[Gastric cancer].
Sato A, Nakamachi M
Gan to kagaku ryoho. Cancer & chemotherapy 36 ( 2 ) 176 - 81 2009.2
-
A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer.
Yoshikawa T, Tsuburaya A, Shimada K, Sato A, Takahashi M, Koizumi W, Yoshizawa Y, Nabeshima K, Kimura M, Hataya K, Kobayashi O
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 12 ( 4 ) 212 - 8 2009
-
[Clinical development of chemotherapy for advanced gastric cancer].
Sato A, Nakamachi M
Gan to kagaku ryoho. Cancer & chemotherapy 35 ( 9 ) 1461 - 6 2008.9
-
[A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer].
Suenaga M, Nishina T, Hyodo I, Munakata M, Koizumi W, Mishima H, Sato A, Mizunuma N, Hatake K
Gan to kagaku ryoho. Cancer & chemotherapy 35 ( 2 ) 255 - 60 2008.2
-
[Clinical development of chemotherapy for advanced gastric cancer].
Sato A, Matsukawa M
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 104 ( 2 ) 186 - 93 2007.2
-
[Irinotecan chemotherapy for patients with advanced or relapsed pancreatic neoplasm].
Sekikawa T, Akaike A, Ushio J, Sato A, Matsukawa M
Nihon rinsho. Japanese journal of clinical medicine 64 Suppl 1 203 - 6 2006.1
-
[Pilot-testing of the Japanese version of the EORTC QLQ-STO22 gastric cancer module].
Morita S, Shimozuma K, Sato A, Nakamachi M, Blazeby J, West K, Fukuhara S, Sakamoto J
Gan to kagaku ryoho. Cancer & chemotherapy 31 ( 8 ) 1195 - 9 2004.8
-
A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.
Kondo Y, Terashima M, Sato A, Taguchi T
Japanese journal of clinical oncology 34 ( 4 ) 195 - 201 2004.4
-
[Treatment of elderly patients with colorectal cancer].
Sato A, Shimada K, Sakashita A, Taguchi S
Nihon rinsho. Japanese journal of clinical medicine 61 Suppl 7 552 - 6 2003.9
-
[Mucositis].
Sato A, Sakashita A, Taguchi S
Nihon rinsho. Japanese journal of clinical medicine 61 ( 6 ) 959 - 65 2003.6
-
[Hypersensitivity reactions to cancer chemotherapeutic agents].
Sato A, Sakashita A, Taguchi S
Gan to kagaku ryoho. Cancer & chemotherapy 30 ( 6 ) 793 - 800 2003.6
-
[Chemotherapy of gastric cancer--a review of clinical trials in Japan].
Sato A, Ito T, Tomita T, Nakamura A, Taguchi S
Gan to kagaku ryoho. Cancer & chemotherapy 29 ( 9 ) 1522 - 31 2002.9
-
[Individuated molecular target chemotherapy].
Yamamoto W, Endo W, Sato A, Matsukawa M
Nihon rinsho. Japanese journal of clinical medicine 60 ( 1 ) 168 - 73 2002.1
-
Effectiveness of doxifluridine (5'-DFUR)/docetaxel against advanced/recurrent gastric cancer showing resistance to various anticancer drug regimens.
Sato A, Shimada K, Nakamachi M, Ushio J, Yamamoto W, Kurihara M, Matsukawa M
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 5 ( 4 ) 233 - 6 2002